

Date: 09/06/2025

To

BSE Limited  
Dept. of Corporate Services,  
Floor 25, PJ Towers,  
Dalal Street, Mumbai-400001

**Scrip Code: 526445**

Dear Sir/Madam,

**Sub: Adjournment of Board meeting and Detailed reasons for delay in submission of audited financial results (standalone & consolidated) for the quarter and year ended 31<sup>st</sup> March 2025**

We would like to inform that the Company is required to submit the audited financial results (standalone & consolidated) for the quarter and year ended 31<sup>st</sup> March 2025, on or before 30<sup>th</sup> May 2025, as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company, vide its announcement dated 27<sup>th</sup> May 2025, informed that the Board meeting for approving the said results would be convened by 9<sup>th</sup> June 2025, after the due date, since the consolidation of results from our subsidiaries combined along with completion of internal and external audit processes of the company are taking more time than estimated to complete the preparation of the results.

However, the Company understands that the finalisation of audited financial results (standalone and consolidated) for the quarter and year ended 31<sup>st</sup> March 2025 requires some more time and hence the Board meeting for approval of said results planned for today is adjourned to 12<sup>th</sup> June 2025.

Furthermore, we would like to bring to your attention that the Trading Window will remain closed for dealing in securities of the Company for all Designated Persons until 48 hours from the declaration of the audited Financial Results (standalone & consolidated) for the quarter and year ended 31<sup>st</sup> March 2025.

Meeting commenced at 04:00 pm and concluded at 08:00 pm.

Thanking you,

Yours faithfully,

**For Indrayani Biotech Limited**

**Swaminathan G**  
**Whole-time Director**  
**DIN: 02481041**

Encl.: as above